Head-to-head evidence
Cannabidiol (Epidiolex) vs JZP926
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: cannabinoid · full Epilepsy pipeline
Cannabidiol (Epidiolex)
Marketed by Jazz Pharmaceuticals and partners
NCT02224573 · Phase 3 · completed
This is a genuine open-label extension trial: the title explicitly states 'Open Label Extension Study,' and eligibility required participants to have completed the treatment phase of the prior randomized, double-blind, placebo-controlled core studies (NCT02091206, NCT02091375, NCT02224703, NCT02224560, NCT02224690). It used a single group of 681 participants with no randomization, no blinding, and no comparator arm, so it cannot provide comparative evidence on its own. The primary outcomes were mostly safety measures plus descriptive changes in seizure frequency, and no inferential statistical comparison was conducted.
Next expected readout: August 2027 · NCT05044819 (registry estimate)
JZP926
Developed by Jazz Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT07233239 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cannabidiol (Epidiolex)'s landscape · JZP926's landscape